Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its financial results release for the first nine months of 2024. The results will be announced after U.S. markets close on November 13, 2024, followed by an analyst conference call on November 14, 2024, at 8:00 am ET. The conference call will be accessible via webcast through Alvotech's investor portal, with replay available for 90 days after the event.
Alvotech (NASDAQ: ALVO), un'azienda biotech globale focalizzata sullo sviluppo di medicinali biosimilari, ha programmato la pubblicazione dei risultati finanziari per i primi nove mesi del 2024. I risultati saranno annunciati dopo la chiusura dei mercati statunitensi il 13 novembre 2024, seguiti da una call con gli analisti il 14 novembre 2024 alle 8:00 ET. La conferenza sarà accessibile tramite webcast attraverso il portale degli investitori di Alvotech, con la registrazione disponibile per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global enfocada en el desarrollo de medicamentos biosimilares, ha programado la publicación de resultados financieros para los primeros nueve meses de 2024. Los resultados se anunciarán después del cierre de los mercados estadounidenses el 13 de noviembre de 2024, seguido de una conferencia telefónica con analistas el 14 de noviembre de 2024 a las 8:00 a.m. ET. La llamada estará disponible a través de un webcast a través del portal de inversores de Alvotech, con grabación accesible durante 90 días después del evento.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품 개발에 집중하는 글로벌 생명공학 회사로, 2024년 첫 아홉 달 동안의 재무 결과 발표를 예정하고 있습니다. 이 결과는 2024년 11월 13일 미국 시장 종료 후 발표되며, 이어서 2024년 11월 14일 오전 8시(동부 시간)에 애널리스트 컨퍼런스 콜이 진행됩니다. 이 컨퍼런스 콜은 Alvotech 투자자 포털을 통해 웹캐스트로 접속 가능하며, 이벤트 후 90일 동안 재생이 가능합니다.
Alvotech (NASDAQ: ALVO), une entreprise biotechnologique mondiale spécialisée dans le développement de médicaments biosimilaires, a prévu la publication de ses résultats financiers pour les neuf premiers mois de 2024. Les résultats seront annoncés après la clôture des marchés américains le 13 novembre 2024, suivi d'une conférence téléphonique avec les analystes le 14 novembre 2024 à 8h00 ET. La conférence sera accessible par webcast via le portail des investisseurs d'Alvotech, avec un replay disponible pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung von Biosimilars konzentriert, hat die Veröffentlichung der finanziellen Ergebnisse für die ersten neun Monate des Jahres 2024 angesetzt. Die Ergebnisse werden nach dem Schluss der US-Märkte am 13. November 2024 bekannt gegeben, gefolgt von einer Analysten-Konferenz am 14. November 2024 um 8:00 Uhr ET. Die Konferenz wird über ein Webcast über das Investorenportal von Alvotech zugänglich sein, und sind für 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended September 30, 2024, after U.S. markets close on Wednesday, November 13, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Thursday November 14, 2024, at 8:00 am ET (13:00 GMT).
Live audio of the conference call will also be webcast and available to members of the news media, investors, and the general public. Access information is posted on Alvotech’s investor portal https://investors.alvotech.com. A direct link to the event, with a link to the webcast and separate call-in information for analysts can be found at https://investors.alvotech.com/events/event-details/q3-2024-earnings. The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (France), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.
FAQ
When will Alvotech (ALVO) release its Q3 2024 financial results?
When is Alvotech's (ALVO) Q3 2024 earnings conference call?
How can I access Alvotech's (ALVO) Q3 2024 earnings call?
